Head & Neck Cancer Pipeline and Market Examined in In-demand GBI Research Study Available at MarketPublishers.com26 Apr 2017 • by Natalie Aster
LONDON – There is a small set of marketed products in the head and neck cancer (HNC) market, comprising cancer immunotherapies, chemotherapies and receptor tyrosine kinase inhibitor products. The pipeline is of a moderate size, with close to 340 products active across all the development stages. First-in-class drugs only make up around a third of the pipeline, and account for just under 40% of products with a disclosed target.
Cancer immunotherapies represent the most extensively examined group of first-in-class targets. The first-in-class drug targets under discussion have exhibited promising efficacy profiles, and a number of them demonstrate the ability to chemosensitise cancer cells.
The key factors driving the market comprise a large patient population, a high probability of disease recurrence for treated patients, the generally poor outcome, the growing patient population in case disease prognosis can be enhanced, a dearth of targeted treatment options in the marketplace, and a clear understanding of the pathophysiology of the disease that has developed during the past ten years.
Owing to the highly polygenic and sophisticated nature of HNC, which has manifold classifications of subtypes, there is little likelihood that a single target inhibition will be enough to considerably improve the survival of patients. The other way round, the concurrent use of multiple targeted therapies – alongside other available treatment modalities – is likely to improve treatment outcomes.
In-demand report “Frontier Pharma: Head and Neck Cancer” created by GBI Research offers an in-depth and all-round assessment of the innovation in HNC space with respect to the entire pipeline and today’s market landscape; alongside limelights the deals landscape pertaining to first-in-class drug products, and identifies the major in-licensing opportunities.
It includes detailed insights into HNC; reviews the changing molecular target landscape between the marketplace and the pipeline, encompassing specific key aspects of innovation in the pipeline. The study sheds light on the pipeline for first-in-class therapies, examines them basing on phase, type of molecule, and molecular target.
The report identifies and evaluates first-in-class molecular targets, specifically focusing on early-stage programmes for which clinical usage is yet to be assessed, alongside literature overviews on new molecular targets. Furthermore, the co-development and licensing deals pertaining to HNC therapies are examined the report.
More in-demand reports by this publisher can be found at GBI Research page.